ReviewJournal of intensive care2014
Update in acute respiratory distress syndrome.
Review in Journal of intensive care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04653831 (Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial
Who cites it
32 citing papers in PubMed, 91 citations in OpenAlex.
- Fludarabine attenuates inflammation and dysregulated autophagy in alveolar macrophages via inhibition of STAT1/IRF1 pathway.Laboratory animal research · 2025Article
- The complex lipid, SPPCT-800, reduces lung damage, improves pulmonary function and decreases pro-inflammatory cytokines in the murine LPS-induced acute respiratory distress syndrome (ARDS) model.Pharmaceutical biology · 2022Article
- Review
- Effect of corticosteroid therapy in the early phase of acute respiratory distress syndrome: a propensity-matched cohort study.The Korean journal of internal medicine · 2021Article
- Apoptotic cell therapy for cytokine storm associated with acute severe sepsis.Cell death & disease · 2020Article
- Nitric Oxide Releasing Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening.Frontiers in bioengineering and biotechnology · 2020Article
- Article
- Carnosic acid protects against lipopolysaccharide-induced acute lung injury in mice.Experimental and therapeutic medicine · 2019Article
- Distinct Metabolic Endotype Mirroring Acute Respiratory Distress Syndrome (ARDS) Subphenotype and its Heterogeneous Biology.Scientific reports · 2019Article
- Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.Frontiers in immunology · 2019Article
- Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine.Journal of inflammation (London, England) · 2019Review
- In-vitro evaluation of limitations and possibilities for the future use of intracorporeal gas exchangers placed in the upper lobe position.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2018Article
- New Insights into the Immune Molecular Regulation of the Pathogenesis of Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2018Review
- Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2017Article
- The prognostic value of N-terminal proB-type natriuretic peptide in patients with acute respiratory distress syndrome.Scientific reports · 2017Article
- α-bisabolol-loaded lipid-core nanocapsules reduce lipopolysaccharide-induced pulmonary inflammation in mice.International journal of nanomedicine · 2017Article
- Pulmonary manifestation ofRespiratory medicine case reports · 2017Article
- Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia.Cell biology and toxicology · 2016Article
- Observational
- [Depressive, anxiety and posttraumatic stress disorders as long-term sequelae of intensive care treatment].Der Nervenarzt · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) is characterized by permeability pulmonary edema and refractory hypoxemia. Recently, the new definition of ARDS has been published, and this definition suggested severity-oriented respiratory treatment by introducing three levels of severity according to PaO2/FiO2 and positive end-expiratory pressure. Lung-protective ventilation is still the key of better outcome in ARDS. Through randomized trials, short-term use of neuromuscular blockade at initial stage of mechanical ventilation, prone ventilation in severe ARDS, and extracorporeal membrane oxygenation in ARDS with influenza pneumonia showed beneficial efficacy. However, ARDS mortality still remains high. Therefore, early recognition of ARDS modified risk factors and the avoidance of aggravating factors during the patient's hospital stay can help decrease its development. In addition, efficient antifibrotic strategies in late-stage ARDS should be developed to improve the outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.